Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy crawled date : 2021 - 11 - 03 save search
NexImmune to Present at The Society for Immunotherapy of Cancer 36th Anniversary Annual Meeting
Published: 2021-11-03 (Crawled : 19:00) - biospace.com/
NEXI | $3.43 -1.53% 13K
|
|
| O: -1.46%
H: 2.26%
C: 0.17%
immunotherapy therapy cancer
Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission
Published: 2021-11-03 (Crawled : 13:00) - globenewswire.com
NERV | $2.53 0.0% 3.9K
|
Health Technology
|
| O: -12.16%
H: 8.46%
C: 8.46%
treatment fda schizophrenia potential therapy submission roluperidone
Alkermes to Present Data on Nemvaleukin Alfa at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
Published: 2021-11-03 (Crawled : 12:15) - biospace.com/
ALKS | $24.66 1.65% 1.62% 1.7M
|
Health Technology
|
| O: -2.41%
H: 3.58%
C: 3.48%
immunotherapy therapy cancer nemvaleukin
COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder
Published: 2021-11-03 (Crawled : 12:15) - globenewswire.com
CMPS | $8.07 -2.18% -2.23% 890K
|
Health Technology
|
| O: 3.74%
H: 1.26%
C: 0.35%
therapy trial comp360 psilocybin
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
Published: 2021-11-03 (Crawled : 12:00) - biospace.com/
AVRO | $1.195 -1.24% -1.26% 350K
|
Health Technology
|
| O: 2.99%
H: 0.0%
C: 0.0%
disease fda rare pediatric disease designation gene therapy therapy syndros designation rare avr-rd-05 rd-05 mps-ih
Taysha Gene Therapies to Release Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10
Published: 2021-11-03 (Crawled : 12:00) - biospace.com/
TSHA | $2.355 -6.92% -7.43% 790K
|
Health Technology
|
| O: 2.69%
H: 1.25%
C: -0.42%
financial results gene therapies results conference gene therapy therapy
BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Canavan Disease
Published: 2021-11-03 (Crawled : 12:00) - biospace.com/
BBIO | $25.02 -1.73% -1.76% 1.5M
|
Health Technology
|
| O: 0.2%
H: 0.0%
C: 0.0%
disease phase 1 gene therapy therapy trial phase 2
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.